Company Overview of MyoKardia, Inc.
MyoKardia, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is MYK-461, a small molecule that is in three Phase I clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy (HCM). The company also develops DCM-1, a product candidate that treats heritable dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart. In addition, it develops HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients; and LUS-1...
333 Allerton Avenue
South San Francisco, CA 94080
Founded in 2012
Key Executives for MyoKardia, Inc.
Chief Executive Officer, President and Director
Compensation as of Fiscal Year 2015.
MyoKardia, Inc. Key Developments
MyoKardia Seeks Acquisitions
Sep 28 15
MyoKardia, Inc. is seeking acquisitions. MyoKardia intends to use the net proceeds from IPO to in-license, acquire or invest in new businesses, technology or assets.
MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy
Mar 3 15
MyoKardia, Inc. announced it has initiated dosing in a Phase 1 clinical trial of MYK-461. MYK-461 is the first ever therapy designed to target the underlying cause of hypertrophic cardiomyopathy (HCM), the most common heritable cardiovascular disease. Patients with HCM are born with a mutation that causes over-contraction of the heart muscle cells, leading to thickening and stiffening of the heart muscle. Patients with HCM live with often debilitating disease symptoms including shortness of breath, chest pain and fainting spells. Complications of HCM include progressive heart failure, abnormal heart rhythms, stroke and sudden cardiac death. MyoKardia is developing a portfolio of potential treatments for HCM, each of which is designed to specifically target one of the underlying molecular mechanisms causing the disease. MYK-461 is the first potential treatment in MyoKardiaâ s HCM portfolio to enter clinical development. MYK-461 has been designed to correct one of the most common molecular mechanisms causing HCM, and the clinical program will evaluate patients whose disease is caused by this specific mechanism, as identified by genetic screening. In conjunction with the initiation of MYK-461â s Phase 1 study, the company also announced the expansion of its management team with the appointment of Ingrid Boyes to senior vice president, human resources and Steven Chan to vice president, corporate controller.
MyoKardia, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015
Feb 18 15
MyoKardia, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 20, 2015